Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / license-agreement-execution.docx
license-agreement-execution.docx
Parties
Penterra Pharmaceuticals Corp
Hong Kong SA
Meridian Korea Inc
Meridian Bio Australia Pty Ltd
Alkerra Manufacturing Inc
Sublicense Inc
Dates
October 2, 2023
October 20, 2023
July 18, 2023
April 20, 2025
October 20, 2026
October 20, 2028
October 6, 2023
Amounts
$18,000,000
$32,000,000
$25,000,000
$45,000,000
$120,000,000
$180,000,000
$50,000,000
$4,000,000
$100,000,000
$11,000,000
Obligations
"Calendar Quarter" means each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30, and December 31, respectively; provided that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the first to occur of March 31, June 30, September 30, or December 31 thereafter, and the last Calendar Quarter of the Term shall end on the effective date of expiration or termination of this Agreement
Sales for compassionate use, named patient supply, clinical trial purposes, or other pre-commercial supply shall not constitute a First Commercial Sale
"IND" means an Investigational New Drug application filed with a Regulatory Authority, or the equivalent thereof (including a Clinical Trial Application), in any country of the Territory, that is required to be filed before commencing clinical trials of a Licensed Product in such country
In no event shall any particular amount be deducted more than once in calculating Net Sales
Sales or transfers of Licensed Products between or among Licensee, its Affiliates, and its sublicensees shall not be included in Net Sales unless such Licensed Products are consumed by the transferee and not resold to a Third Party
Transfers of Licensed Products for charitable, compassionate use, promotional, clinical trial, or sampling purposes shall be excluded from Net Sales